MEIP Share Price

Open 1.56 Change Price %
High 1.56 1 Day -0.01 -0.65
Low 1.53 1 Week 0.06 4.08
Close 1.53 1 Month 0.09 6.25
Volume 182383 1 Year 0.22 16.79
52 Week High 2.28
52 Week Low 0.87
MEIP Important Levels
Resistance 2 1.56
Resistance 1 1.55
Pivot 1.54
Support 1 1.51
Support 2 1.50
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
APRI 2.86 89.40%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
APRI 2.86 89.40%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
SKBI 0.12 50.00%
UNXL 1.69 34.13%
LIFE 3.25 32.65%
CHCI 2.42 29.41%
GLBS 6.17 27.22%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

MEI Pharma, Inc. (NASDAQ: MEIP)

MEIP Technical Analysis 3
As on 18th Jan 2017 MEIP Share Price closed @ 1.53 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.50 & Buy for SHORT-TERM with Stoploss of 1.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
MEIP Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MEIP Other Details
Segment EQ
Market Capital 24491034.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.meipharma.com
MEIP Address
MEIP
11975 El Camino Real
Suite 101
San Diego, CA 92130
United States
Phone: 858-792-6300
MEIP Latest News
Investors Swarm in on MEI Pharma, Inc. (NASDAQ:MEIP)   Prospect Journal   - 17th Jan 17
Will The Needle Move For MEI Pharma, Inc. (NASDAQ:MEIP) Shares This Earnings ...   Wall Street Beacon   - 17th Jan 17
MEI Pharma (MEIP) Stock: Here's What You Need To Know   CNA Finance (press release)   - 06th Dec 16
MEI Pharma Reports Fiscal Year 2016 Results   PR Newswire (press release)   - 06th Sep 16
MEI Pharma shares jump 51% in pre-market trade after $20 mln drug deal   MarketWatch   - 08th Aug 16
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and ...   PR Newswire (press release)   - 08th Aug 16
MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA ...   PR Newswire (press release)   - 01st Aug 16
MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A ...   PR Newswire (press release)   - 20th Apr 16
MEI Pharma to Present at Needham Healthcare Conference   PR Newswire (press release)   - 05th Apr 16
Can MEI Pharma Survive?   24/7 Wall St.   - 24th Mar 15
Interactive Technical Analysis Chart MEI Pharma, Inc. ( MEIP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MEI Pharma, Inc.
MEIP Business Profile
MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (Novogen). As of September 26, 2011, Novogen owned approximately 51.5% interests in the Company. The Company's has two geographic segments: the United States and Australia. The Company has two clinical product development programs, which include NADH Oxidase Inhibitors and Mitochondrial Inhibitors. NADH Oxidase Inhibitors includes Phenoxodiol and ME-143. Mitochondrial Inhibitors includes NV-128 and ME-344. Marshall Edwards Pty Ltd. is a wholly owned subsidiary of the Company. In February 2013, Novogen Limited completed its exchanged offer through which it was to split off its 63.5% interest in the Company.